ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study

Xiao, Yanni; Lu, Di; Lei, Mingxing; Xie, Wenzhuan; Chen, Yaoxu; Zheng, Yating; Wang, Chunli; Zhao, Jing; Zhu, Zhen; Zhao, Xiaochen; Huang, Mengli; Lin, Youen*; Li, Zhongjun*; Yang, Li*南方医科大学; 重庆大学
Annals of Translational Medicine2021-11DOI: 10.21037/atm-21-5449
13被引8阅读
引用收藏
分享

摘要

Background: Disruption of the DNA damage repair (DDR) gene is related to cancer progression, treatment selection, and is subjected to radiation and targeted therapies with limited success. This paper conducted a comprehensive analysis to explore the distribution of DDR mutations in Chinese pan-cancer patients. @@@ Methods: A total of 10,284 consecutive cases were analyzed in 24 cancer types [non-small cell lung cancer (NSCLC) 29.0%, liver 12.0%, colorectum 10.7%, etc.]. Tumor tissue samples were subjected to next generation sequencing (NGS) using a 381 gene panel incorporating 100 microsatellite loci. The association of deleterious somatic DDR mutation (del-sDDR(mut)) with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1) expression of pan-cancers was evaluated. Genomic and clinical data from public cohorts of immunotherapy were analyzed to demonstrate the association between del-sDDR(mut) and clinical survival. @@@ Results: Del-sDDR(mut) were found in 802 (7.6%) of all cases, and were most common in cancers of the endometrium, prostate, bladder, etc. cancer with a higher TMB also had a higher prevalence of mutations in DDR pathways. The results of the ridge regression analysis showed that 20 DDR genes were significantly associated with TMB [false discovery rate (FDR) <0.01]. A total of 8,899 patients had both TMB and MSIdata in pan-cancers. Seventy-four percent of patients with MSI-high (MSI-H) were accompanied by del-sDDR(mut)/TMB-high (TMB-H). The largest proportion of patients with microsatellite stability (MSS) with DDR mutations were classified as TMB-H. The top 6 tumors (NSCLC, melanoma, esophagus, head and neck, thyroid, and mediastinal) had the highest prevalence of PD-L1 >= 1%, and DDR mutations were significantly associated with a higher percent of PD-L1 positive (P<0.05). Furthermore, in the immune cohort analysis of NSCLC, patients with del-sDDR(mut) significantly improved median progression-free survival (mPFS) and median overall survival (mOS) compared to wild-type DDR patients (P=0.002 and P=0.043), with higher TMB observed (P<0.001). @@@ Conclusions: This study explored the association of DDR mutations with TMB, MSI-H, and PD-L1 expression, and revealed that patients with DDR mutations have a significantly improve prognosis than wild-type patients on immunotherapy.

学科与关键词

关键词
DNA damage repair deficiency (DDR deficiency)tumor mutational burden (TMB)somatic mutationpan-cancer
相关
加载中…
  • DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
    Gu, Weiguang*; Zhuang, Wenya; Zhuang, Mengxia; He, Minhong; Li, ZhihuaDiagnostic Pathology, 2023, 18(1): 119.
  • DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study
    Xiao, Zhiwei; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Huang, Mengli; Bai, Yuezong; Chen, Zhe-Sheng; Kinslow, Connor J.; Loh, Jerold; Lin, Lizhu*Translational Lung Cancer Research, 2022, 11(12): 2539-U159.
  • A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer
    Ding, Ke; He, Youhua; Wei, Jinfen; Fu, Shuying; Wang, Jiajian; Chen, Zixi; Zhang, Haibo; Qu, Yimo; Liang, Keying; Gong, Xiaocheng; Qiu, Li; Chen, Dong; Xiao, Botao*; Du, Hongli*Frontiers in Immunology, 2022, 13: 943090.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Translational Medicine
发表日期
2021-11
卷期
第 9 卷, 第 22 期
页码
1661
DOI
10.21037/atm-21-5449
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82003384]; Fundamental Research Funds for the Central Universities [2020CDJYGSG003]; Chongqing Talents Program [CQYC2020058022]; Scientific Research Foundation from Chongqing University [02210011044110]; Innovation and Attracting Talents Program for College and University ("111" Project), China [B06023]

作者

  • X

    Xiao, Yanni (第一作者)

    chongqing univ · third mil med univ, affiliated hosp 2

  • L

    Lu, Di

    southern med univ

查看全部 14 位作者收起作者
  • L

    Lei, Mingxing

    chongqing univ

  • X

    Xie, Wenzhuan

  • C

    Chen, Yaoxu

  • Z

    Zheng, Yating

  • W

    Wang, Chunli

    chongqing univ

  • Z

    Zhao, Jing

  • Z

    Zhu, Zhen

  • Z

    Zhao, Xiaochen

  • H

    Huang, Mengli

  • L

    Lin, Youen (通讯)

  • L

    Li, Zhongjun (通讯)

    third mil med univ, affiliated hosp 2

  • Y

    Yang, Li (通讯)

    chongqing univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417